Dapagliflozin Propanediol Monohydrate

达格列净丙二醇一水化物

Report date: 2026/05/26 20:00:28
NME

Base Information

Drug NameDapagliflozin Propanediol Monohydrate
Drug Alias NameDapagliflozin propylene glycolate hydrate丙二醇达格列净水合物dapagliflozinum达格列嗪安达唐 +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSodium/glucose cotransporter 2 inhibitors
TargetsSodium/glucose cotransporter 2
Therapy Area/IndicationsDiabetic peripheral neuropathyRejection of renal transplantationCoronavirus Disease 2019 (COVID-19) +[77] 
Global Approved IndicationsDiabetes Mellitus, Type 2
Approved Indications in ChinaDiabetes Mellitus, Type 2
Original Approved Country/TerritoryEU
Original Approved Date2012/11/11
Country/TerritoryCzechiaBelgiumBulgaria +[54] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesStrasbourg University HospitalInstituto Nacional De Ciencias Medicas Y Nutricion Salvador ZubiranCanadian Institutes Of Health Research (Cihr) +[52] 
Inactive CompaniesHanmi Pharmaceutical Co LtdBristol-Myers Squibb Manufacturing CoBristol Myers Squibb Srlcompany +[17] 
Active IndicationsRejection of renal transplantationCoronavirus Disease 2019 (COVID-19)Solid tumours +[64] 
Inactive IndicationsDiabetic peripheral neuropathyWeight LossHypoglycemia +[13] 

Other Information

ATC CodeA10BK01
Related LinksWikipediaDrugBankKEGG